论文部分内容阅读
52例慢性淋巴细胞白血病(CLL)患者用fludarabine治疗,25mg/m~2,静脉滴注,每天1次,共5天。同期用fludarabine治疗了18例其他类型的慢性淋巴细胞增殖性疾病。CLL按Binet法分期。AIHA按标准的方法诊断:血红蛋白降低伴球形红细胞、网织红细胞增多,尿胆素原增高。直接抗人球蛋白试验(DAT)阳性。 在fludarabine治疗后,12例患者(男性7例,女性5例,平均年龄59岁,范围49～81岁)产生温抗体型AIHA,占用该法治疗患者的21％。所有患者有B期或C期疾病,在治疗时有高的白细胞计数。因预先血小板减少,3例患者fludarabine剂量减半。9/12例患者既往无
Twenty-two patients with chronic lymphocytic leukemia (CLL) were treated with fludarabine, 25 mg/m~2 intravenous drip once daily for 5 days. In the same period, 18 cases of other types of chronic lymphocytic proliferative diseases were treated with fludarabine. CLL is divided by Binet method. AIHA is diagnosed according to standard methods: Hemoglobin is reduced with erythrocytes, reticulocytes, and urobilinogen are increased. Direct anti-human globulin test (DAT) positive. After fludarabine treatment, 12 patients (7 males, 5 females, mean age 59 years, range 49-81 years) developed warm antibody type AIHA, which occupies 21% of patients. All patients had B or C disease and had high white blood cell counts during treatment. Due to the previous thrombocytopenia, the dose of fludarabine was halved in 3 patients. 9/12 patients had no previous